title: Release of prostacyclin after erythrocyte adhesion to cultured vascular endothelium.
abstract: Endothelial cell damage is considered to be the initial step in the genesis of thrombosis and atherosclerosis. Recently, the adhesion of erythrocytes from patients with diabetes or sickle cell anemia to endothelial cells was found to be increased and correlated with the severity of vascular complications. We have measured by radioimmunoassay the release of 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha) as an index of prostacyclin (PGI2) production, during red cell adhesion to endothelial cells in culture. The amount of 6-keto-PGF1 alpha released after incubation with normal red cells was similar to that observed with buffer (1.07 +/- 0.32 nmol/10(6) endothelial cells). However, after the adhesion of erythrocytes from patients with diabetes or sickle cell anemia, the amount of 6-keto-PGF1 alpha produced was significantly increased (P less than 0.01) and was correlated with the extent of erythrocyte adhesion (P less than 0.05). Tritium-labeled PGI2 was found to bind to erythrocytes, and the binding was time and concentration dependent. PGI2 release was inhibited by the cyclooxygenase inhibitor (flurbiprofen), whereas red cell adhesion remained unchanged. Fibrinogen potentiated erythrocyte adhesion and PGI2 production. The increase in PGI2 production after the adhesion of red cells from patients with diabetes or sickle cell anemia to endothelial cells indicates that endothelium may be damaged by abnormal erythrocyte adhesion.
authors.forename: J L
authors.initials: JL
authors.lastname: Wautier
authors.forename: D
authors.initials: D
authors.lastname: Pintigny
authors.forename: J
authors.initials: J
authors.lastname: Maclouf
authors.forename: M P
authors.initials: MP
authors.lastname: Wautier
authors.forename: E
authors.initials: E
authors.lastname: Corvazier
authors.forename: J
authors.initials: J
authors.lastname: Caen
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000244:Adenosine Diphosphate / Q000097:blood; D000255:Adenosine Triphosphate / Q000097:blood; D000328:Adult; D000755:Anemia, Sickle Cell / Q000097:blood*; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000378:metabolism; D001792:Blood Platelets / Q000502:physiology; D001798:Blood Proteins / Q000378:metabolism; D001808:Blood Vessels / Q000502:physiology*; D002448:Cell Adhesion; D002478:Cells, Cultured; D016861:Cyclooxygenase Inhibitors; D003920:Diabetes Mellitus / Q000097:blood*; D004727:Endothelium / Q000502:physiology; D011464:Epoprostenol / Q000097:blood*; D004912:Erythrocytes / Q000378:metabolism / Q000502:physiology*; D005340:Fibrinogen / Q000502:physiology; D005480:Flurbiprofen / Q000494:pharmacology; D006801:Humans; D007962:Leukocytes / Q000502:physiology; D008875:Middle Aged; D010949:Plasma / Q000502:physiology; D011460:Prostaglandins F / Q000096:biosynthesis; D013929:Thromboxane B2 / Q000097:blood
chemical_list: D001095:Arachidonic Acids; D001798:Blood Proteins; D016861:Cyclooxygenase Inhibitors; D011460:Prostaglandins F; D016718:Arachidonic Acid; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D005480:Flurbiprofen; D000244:Adenosine Diphosphate; D000255:Adenosine Triphosphate; D005340:Fibrinogen; D011464:Epoprostenol